Abbott Laboratories (ABT)vsNovo Nordisk A/S (NVO)
ABT
Abbott Laboratories
$104.83
+0.74%
HEALTHCARE · Cap: $180.82B
NVO
Novo Nordisk A/S
$36.33
-1.52%
HEALTHCARE · Cap: $165.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 597% more annual revenue ($309.06B vs $44.33B). NVO leads profitability with a 33.1% profit margin vs 14.7%. ABT appears more attractively valued with a PEG of 1.52. NVO earns a higher WallStSmart Score of 55/100 (C).
ABT
Buy51
out of 100
Grade: C-
NVO
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-315.5%
Fair Value
$25.23
Current Price
$104.83
$79.60 premium
Margin of Safety
-59.4%
Fair Value
$24.21
Current Price
$36.33
$12.12 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.6%
Generating 2.6B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 61 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 44.5%
Large-cap with strong market position
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.4% revenue growth
Weak financial health signals
Weak financial health signals
Expensive relative to growth rate
Revenue declined 7.6%
Earnings declined 4.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
ABT profiles as a value stock while NVO is a declining play — different risk/reward profiles.
ABT carries more volatility with a beta of 0.74 — expect wider price swings.
ABT is growing revenue faster at 4.4% — sustainability is the question.
ABT generates stronger free cash flow (2.6B), providing more financial flexibility.
Bottom Line
NVO scores higher overall (55/100 vs 51/100), backed by strong 33.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?